Levetiracetam Tablet, Film Coated
Product Images NDC 65862-246

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 65862-246). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aurobindo Pharma Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1: Responder Rate (≥50% Reduction From Baseline) In Study 1 (Levetiracetam Fig1)

A bar chart titled 'Responder Rate (≥50% Reduction from Baseline) in Study 1,' displaying the percentage of patients achieving response. The chart compares placebo, Levetiracetam 1000 mg/day, and Levetiracetam 3000 mg/day groups, showing responder rates of 7.4%, 37.1%, and 39.6%, respectively, with statistical significance indicated against placebo.*

FDA Label Image

Package Label-principal Display Panel (1000 mg (500 Tablets Bottle))

Label for Levetiracetam Tablets USP 1000 mg film-coated tablets by Aurobindo Pharma Limited. The label indicates a package size of 500 tablets, includes storage instructions, and provides distributor information for Aurobindo Pharma USA, Inc. The label states 'Rx only' and notes dispensing guidance for pharmacists.*

FDA Label Image

Figure 2: Responder Rate (≥50% Reduction From Baseline) In Study 2: Period A (Levetiracetam Fig2)

A bar chart titled 'Responder Rate (≥50% Reduction from Baseline) in Study 2: Period A' showing the percentage of patients responding to treatments. The x-axis represents three categories: Placebo (N=111), Levetiracetam 1000 mg/day (N=106), and Levetiracetam 2000 mg/day (N=105). The y-axis shows the percentage of patients ranging from 0% to 45%. Placebo has a 6.3% responder rate, Levetiracetam 1000 mg/day has a 20.8% responder rate, and Levetiracetam 2000 mg/day has a 35.2% responder rate, with both Levetiracetam groups marked as statistically significant versus placebo.*

FDA Label Image

Figure 3: Responder Rate (≥50% Reduction From Baseline) In Study 3 (Levetiracetam Fig3)

Bar chart showing responder rate defined as 50% or greater reduction from baseline in Study 3. The chart compares placebo with 14.4% responders (N=104) to Levetiracetam 3000 mg/day with 39.4% responders (N=180). Statistical significance versus placebo is indicated.*

FDA Label Image

Figure 4: Responder Rate (≥ 50% Reduction From Baseline) In Study 4 (Levetiracetam Fig4)

Bar chart titled 'Responder Rate (≥ 50% Reduction from Baseline) in Study 4' comparing the percentage of patients achieving a 50% or greater reduction from baseline between placebo (19.6%) and levetiracetam (44.6%) groups. The chart indicates a statistically significant difference marked by an asterisk for levetiracetam versus placebo.*

FDA Label Image

Figure 5: Responder Rate For All Patients Ages 1 Month To < 4 Years (≥ 50% Reduction From Baseline) In Study 5 (Levetiracetam Fig5)

A bar chart titled 'Responder Rate for All Patients Ages 1 Month to < 4 Years (>= 50% Reduction from Baseline) in Study 5' comparing placebo and levetiracetam. The vertical axis shows percentage of patients from 0% to 45%, with placebo at 19.6% and levetiracetam at 43.1%, indicating a statistically significant difference.*

FDA Label Image

Figure 6: Responder Rate (≥50% Reduction From Baseline) In Pgtc Seizure Frequency Per Week In Study 7 (Levetiracetam Fig6)

A bar chart titled 'Responder Rate (≥50% Reduction from Baseline) in PGTC Seizure Frequency per Week in Study 7' compares the percentage of patients responding to Placebo and Levetiracetam. The y-axis shows the percentage of patients from 0% to 100%. Placebo group (N=84) shows a 45.2% responder rate, while Levetiracetam group (N=79) shows a 72.2% responder rate, with a notation indicating statistical significance versus placebo.*

FDA Label Image

Package Label-principal Display Panel (250 mg (500 Tablets Bottle))

Label for Levetiracetam Tablets USP 250 mg film-coated tablets from Aurobindo Pharma Limited. The label displays the dosage strength (250 mg) prominently in green, the total tablet count (500 tablets), and storage instructions. It includes distribution information for Aurobindo Pharma USA, Inc. and notes the product is made in India.*

FDA Label Image

Package Label-principal Display Panel (500 mg (500 Tablets Bottle))

Levetiracetam Tablets USP 500 mg film-coated tablets label showing key regulatory and manufacturer information. The label includes dosage form and strength, quantity (500 tablets), distributor details (Aurobindo Pharma USA, Inc.), storage instructions, pharmacist dispensing instructions, and barcode. The product is manufactured by Aurobindo Pharma Limited and made in India.*

FDA Label Image

Package Label-principal Display Panel (750 mg (500 Tablets Bottle))

Levetiracetam Tablets USP 750 mg film-coated tablet label from Aurobindo Pharma USA, Inc. The label indicates the NDC 65862-247-05, package size of 500 tablets, and storage instructions. It states to dispense with medication guide and includes distributor contact information with barcode on the right side.*

FDA Label Image

Chemical Structure (Levetiracetam Str)

Chemical structure of levetiracetam, showing its pyrrolidone ring and side chains including an amide group and an ethyl group.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.